← Back to Clinical Trials
Recruiting NCT04793828

NCT04793828 A Transdiagnostic, Self-guided Internet Intervention ("Velibra") for Waitlist Patients With Anxiety Disorders

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04793828
Status Recruiting
Phase
Sponsor Charite University, Berlin, Germany
Condition Panic Disorder With Agoraphobia
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2020-07-04
Primary Completion 2027-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Velibra

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2020-07-04 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The project's aim is to investigate the effect of a transdiagnostic, self-guided, internet-based cognitive behavioral therapy program in waitlist patients with anxiety disorders.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of panic disorder with or without agoraphobia, social anxiety disorder, or generalized anxiety disorder * Knowledge of German that is sufficient for engaging with the treatment and responding to the questionnaires * Written informed consent * Internet access Exclusion Criteria: * Diagnoses of severe mental comorbidities (e.g., schizophrenia, severe major depression, borderline personality disorder) * Acute suicidality * Started or changed anxiolytic pharmacotherapy recently (currently or in the past four weeks)

Contact & Investigator

Central Contact

Anna Wehrheim, M.Sc.-Psych.

✉ anna.wehrheim@charite.de

📞 +49 30 450 517 017

Principal Investigator

Lena Pyrkosch, Dipl.-Psych.

PRINCIPAL INVESTIGATOR

Department of Psychiatry and Psychotherapy, Charité Campus Mitte - Universitätsmedizin Berlin

Frequently Asked Questions

Who can join the NCT04793828 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Panic Disorder With Agoraphobia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04793828 currently recruiting?

Yes, NCT04793828 is actively recruiting participants. Contact the research team at anna.wehrheim@charite.de for enrollment information.

Where is the NCT04793828 trial being conducted?

This trial is being conducted at Berlin, Germany.

Who is sponsoring the NCT04793828 clinical trial?

NCT04793828 is sponsored by Charite University, Berlin, Germany. The principal investigator is Lena Pyrkosch, Dipl.-Psych. at Department of Psychiatry and Psychotherapy, Charité Campus Mitte - Universitätsmedizin Berlin. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology